Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.

Medicine (Baltimore) · 2024 · PMC11557104 · PMID 39533634

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Kenmotsu et al [ 16 ] found that the subgroup of patients with EGFR exon 19 deletion in the experimental group showed a trend toward longer PFS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.